These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1234 related articles for article (PubMed ID: 21549516)

  • 41. Larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer.
    Pfister DG; Strong E; Harrison L; Haines IE; Pfister DA; Sessions R; Spiro R; Shah J; Gerold F; McLure T
    J Clin Oncol; 1991 May; 9(5):850-9. PubMed ID: 2016629
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lymph node ratio as a prognostic factor in head and neck cancer patients.
    Chen CC; Lin JC; Chen KW
    Radiat Oncol; 2015 Aug; 10():181. PubMed ID: 26302761
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.
    Xiang M; Holsinger FC; Colevas AD; Chen MM; Le QT; Beadle BM
    Cancer; 2018 Dec; 124(23):4486-4494. PubMed ID: 30332498
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcomes of postoperative simultaneous modulated accelerated radiotherapy for head-and-neck squamous cell carcinoma.
    Moon SH; Jung YS; Ryu JS; Choi SW; Park JY; Yun T; Lee SH; Cho KH
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):140-9. PubMed ID: 20732767
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines.
    Grégoire V; Evans M; Le QT; Bourhis J; Budach V; Chen A; Eisbruch A; Feng M; Giralt J; Gupta T; Hamoir M; Helito JK; Hu C; Hunter K; Johansen J; Kaanders J; Laskar SG; Lee A; Maingon P; Mäkitie A; Micciche' F; Nicolai P; O'Sullivan B; Poitevin A; Porceddu S; Składowski K; Tribius S; Waldron J; Wee J; Yao M; Yom SS; Zimmermann F; Grau C
    Radiother Oncol; 2018 Jan; 126(1):3-24. PubMed ID: 29180076
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST.
    Katsuura T; Kitajima K; Fujiwara M; Terada T; Uwa N; Noguchi K; Doi H; Tamaki Y; Yoshida R; Tsuchitani T; Fujita M; Yamakado K
    Ann Nucl Med; 2018 Aug; 32(7):453-462. PubMed ID: 29858797
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma.
    Hoebers FJ; Pameijer FA; de Bois J; Heemsbergen W; Balm AJ; Schornagel JH; Rasch CR
    Head Neck; 2008 Sep; 30(9):1216-23. PubMed ID: 18642295
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck.
    Nagasaka M; Zaki M; Issa M; Kim H; Abrams J; Sukari A
    Laryngoscope; 2017 Oct; 127(10):2260-2264. PubMed ID: 28271529
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
    Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
    Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of upfront neck dissection in definitive radiotherapy for locally advanced hypopharyngeal squamous cell carcinoma: A single-center retrospective analysis.
    Katano A; Yamashita H; Saito Y; Kobayashi K
    Head Neck; 2024 Nov; 46(11):2815-2823. PubMed ID: 38842032
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of induction chemotherapy for N3 head and neck squamous cell carcinoma.
    Nishikawa D; Hanai N; Ozawa T; Hirakawa H; Suzuki H; Nakashima T; Hasegawa Y
    Auris Nasus Larynx; 2015 Apr; 42(2):150-5. PubMed ID: 25498333
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improving outcomes in veterans with oropharyngeal squamous cell carcinoma through implementation of a multidisciplinary clinic.
    Light T; Rassi EE; Maggiore RJ; Holland J; Reed J; Suriano K; Stooksbury M; Tobin N; Gross N; Clayburgh D
    Head Neck; 2017 Jun; 39(6):1106-1112. PubMed ID: 28370667
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic value of total tumor volume in advanced-stage laryngeal and hypopharyngeal carcinoma.
    Yang CJ; Kim DY; Lee JH; Roh JL; Choi SH; Nam SY; Kim SY
    J Surg Oncol; 2013 Dec; 108(8):509-15. PubMed ID: 24590673
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy.
    Kuhnt T; Mueller AC; Pelz T; Haensgen G; Bloching M; Koesling S; Schubert J; Dunst J
    J Cancer Res Clin Oncol; 2005 Nov; 131(11):758-64. PubMed ID: 16088405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pathologically determined tumor volume vs pathologic T stage in the prediction of outcome after surgical treatment of oropharyngeal squamous cell carcinoma.
    Nixon IJ; Palmer FL; Lakin P; Kattan MM; Lee NY; Ganly I
    JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1151-5. PubMed ID: 24092047
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic impact of tumor volume in patients with stage III-IVA hypopharyngeal cancer without bulky lymph nodes treated with definitive concurrent chemoradiotherapy.
    Chen SW; Yang SN; Liang JA; Lin FJ; Tsai MH
    Head Neck; 2009 Jun; 31(6):709-16. PubMed ID: 19260114
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
    Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
    Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
    Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
    Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Value of intensity-modulated radiotherapy in Stage IV head-and-neck squamous cell carcinoma.
    Dirix P; Nuyts S
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1373-80. PubMed ID: 20362402
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer.
    Kano S; Homma A; Hatakeyama H; Mizumachi T; Sakashita T; Kakizaki T; Fukuda S
    Head Neck; 2017 Feb; 39(2):247-253. PubMed ID: 27617428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.